Research programme: pain therapeutics - AnaBios CorporationAlternative Names: Periheral neuropathy- AnaBios Corporation; TRPA1/TRPV1 modulation- AnaBios Corporation
Latest Information Update: 04 Jan 2017
At a glance
- Originator AnaBios Corporation
- Class Analgesics; Small molecules
- Mechanism of Action TRPA1 protein modulators; TRPV1 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 26 Dec 2016 Preclinical trials in Pain in USA (unspecified route)